Introduction: Somatostatin analogs (SSA) delay progress and decrease symptoms in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). It is not known whether patients’ experiences of injection treatment differ between different SSAs.
Aim(s): To investigate quality of life and treatment experience with SSA in patients with GEP-NETs.
Materials and methods: A cross-sectional study was performed in two Swedish NET centres. Patients with GEP-NET, older than 18 years, with SSA-treatment for less than 3 years and with Ki67<10% were eligible and identified from hospital databases. Patients were sent a questionnaire addressing practical aspects of, and patient anxiety during the most recent SSA injection.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ass. prof. Martin Almquist
To read results and conclusion, please login ...
Further abstracts you may be interested in